Skip to main content

Table 1 Clinical characteristics of non- Candida fungaemia infection

From: Clinical characteristics and risk factors of non-Candida fungaemia

  C. neoformans(n = 6) T. asahii(n = 4) K. ohmeri(n = 1)
Co-morbiditiesa 6 (100%) 4 (100%) 1 (100%)
Immunosuppressant therapy 4(66.7%) 2 (50.0%) 1 (100%)
Renal replacement therapy 2 (33.3%) 2 (50.0%) 1 (100%)
Colonisation by causative yeasts 4 (66.7%) 4 (100%) 1 (100%)
SOFA score, median (range) 9 (1–18) 8 (1–17) 20 (−)
In vitro-active antifungal agent 4 (66.7%) 1 (25.0%) 1 (100%)
30-day mortality 3 (50.0%) 3 (75.0%) 0 (0%)
  1. SOFA: sequential organ failure assessment.
  2. a Co-morbidities of C. neoformans infection include acute respiratory distress syndrome, hepatitis C virus infection, post-living donor liver transplantation (LDLT), systemic lupus erythaematosus, and miliary tuberculosis. Co-morbidities of T. asahii infection include POEMS syndrome, liver cirrhosis, Bechet’s disease, and acute myeloid leukaemia. Co-morbidities of K. ohmeri infection include alcoholic liver cirrhosis and post-LDLT.